Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125247081 | 12524708 | 1 | I | 20160517 | 20160523 | 20160704 | 20160704 | PER | US-ASTRAZENECA-2016SE56160 | ASTRAZENECA | 24448.00 | DY | F | Y | 97.50000 | KG | 20160704 | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125247081 | 12524708 | 1 | PS | BYDUREON | EXENATIDE | 1 | Subcutaneous | ONCE A WEEK | U | 22200 | |||||||||
| 125247081 | 12524708 | 2 | SS | LISINOPRIL HCTZ | HYDROCHLOROTHIAZIDELISINOPRIL | 1 | Oral | DAILY | U | 0 | TABLET | ||||||||
| 125247081 | 12524708 | 3 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | U | 21366 | 5 | MG | TABLET | QD | ||||||
| 125247081 | 12524708 | 4 | C | CARVEDILOL. | CARVEDILOL | 1 | Oral | 0 | 3.125 | MG | BID | ||||||||
| 125247081 | 12524708 | 5 | C | LOVAZA | OMEGA-3-ACID ETHYL ESTERS | 1 | Oral | 0 | 2 | G | QD | ||||||||
| 125247081 | 12524708 | 6 | C | FLUOXETINE HCL | FLUOXETINE HYDROCHLORIDE | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 125247081 | 12524708 | 7 | C | CENTRUM SILVER VITAMIN | 2 | Oral | 0 | 1 | DF | QD | |||||||||
| 125247081 | 12524708 | 8 | C | TYLENOL | ACETAMINOPHEN | 1 | Oral | TWO TIMES A DAY | 0 | ||||||||||
| 125247081 | 12524708 | 9 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 0 | 30 | MG | BID | ||||||||
| 125247081 | 12524708 | 10 | C | CLARINEX | DESLORATADINE | 1 | Oral | 0 | 5 | MG | QD | ||||||||
| 125247081 | 12524708 | 11 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 0 | 600 | MG | QD | ||||||||
| 125247081 | 12524708 | 12 | C | CHOLESTYRAMINE. | CHOLESTYRAMINE | 1 | 0 | ||||||||||||
| 125247081 | 12524708 | 13 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | 0 | ||||||||||||
| 125247081 | 12524708 | 14 | C | CITRA CAL VITAMIN D CITRA CAL VITAMIN D | 2 | 0 | |||||||||||||
| 125247081 | 12524708 | 15 | C | BIOTIN | BIOTIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125247081 | 12524708 | 1 | Type 2 diabetes mellitus |
| 125247081 | 12524708 | 2 | Hypertension |
| 125247081 | 12524708 | 3 | Blood cholesterol abnormal |
| 125247081 | 12524708 | 4 | Hypertension |
| 125247081 | 12524708 | 5 | Blood cholesterol abnormal |
| 125247081 | 12524708 | 6 | Depression |
| 125247081 | 12524708 | 7 | Vitamin supplementation |
| 125247081 | 12524708 | 8 | Arthritis |
| 125247081 | 12524708 | 9 | Gastrooesophageal reflux disease |
| 125247081 | 12524708 | 10 | Hypersensitivity |
| 125247081 | 12524708 | 11 | Diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125247081 | 12524708 | Abdominal discomfort | |
| 125247081 | 12524708 | Anaemia | |
| 125247081 | 12524708 | Blood iron decreased | |
| 125247081 | 12524708 | Body height decreased | |
| 125247081 | 12524708 | Constipation | |
| 125247081 | 12524708 | Diarrhoea | |
| 125247081 | 12524708 | Eating disorder | |
| 125247081 | 12524708 | Eructation | |
| 125247081 | 12524708 | Lipase increased | |
| 125247081 | 12524708 | Nail disorder | |
| 125247081 | 12524708 | Vitamin D decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125247081 | 12524708 | 1 | 201507 | 201605 | 0 | |
| 125247081 | 12524708 | 12 | 20160419 | 0 |